Serving the needs of patient care 

Clinical content on topics that will help to improve patient care and health outcomes showcased by pharmaceutical companies are a valuable part of the WCP 2017. Apart from the scientific programme exhibiting companies are hosting several Industry Symposia.

Monday, 9 October 2017

Pushing back frontiers in neuropsychiatric disease therapy (Dr. Willmar Schwabe GmbH & Co. KG)
11:45 - 13:15 | Hall A2

Chair:
Siegfried Kasper, Austria

Speaker:
Armin von Gunten, Switzerland
Behavioural and psychological symptoms associated with dementia (BPSD): Prevalence, clinical importance and treatment options
Speaker:

Hans-Peter Volz, Germany

Anxiety therapy: Closing the gap between efficacy and safety

Tranylcypromin - effektives und sicheres Management therapieresistenter Depression mit dem Ansatzpunkt Monoaminoxidase (Aristo Pharma GmbH)
11:45 - 13:15 | Hall New York 2
Chair:
Mazda Adli, Germany
 
Speaker:
Manfred Gerlach, Germany
Monoaminoxidase - eine nach wie vor zeitgemäße pharmakologische Zielstruktur der Depressionsbehandlung mit Tranylcypromin
Speaker:
Roland Ricken, Germany
Von Fallberichten und kontrollierten Studien zur Meta-Analyse - Tranylcypromin in der Therapie der Depression
Speaker:
W. A. Nolen, The Netherlands
Klinische Pharmakologie und praktische Therapie von Tranylcypromin: besondere Rolle bei atypischer Depression?
Tuesday, 10 October 2017

Advances in schizophrenia: Why do we need new treatment options? (Otsuka Pharmaceutical Development & Commercialization, Inc  & H. Lundbeck A/S)
11:45 - 13:15 | Hall A5

Chair:
Christoph Correll, USA
 
Speaker:
Celso Arango, Spain
Schizophrenia today and what we need tomorrow
Speaker:
Leslie Citrome, Denmark

Pharmacology of the D2 partial agonists - What they bring to the table

Speaker:
John Kane, Denmark

Brexpiprazole for treatment of patients with acute schizophrenia - The short term perspective

Speaker:
Christoph Correll, USA

Brexpiprazole for relapse prevention in schizophrenia - The long term view

Paving the way to remission from depression (SERVIER Deutschland GmbH)
11:45 - 13:15 | Hall A4
Chair:

Hans-Jürgen Möller, Germany
Co Chair:
Siegfried Kasper, Austria

 
Speaker:
Koen Demyttenaere, Belgium
Meeting the challenge of characterizing depressed patients’ symptoms
Speaker:
Siegfried Kasper, Austria
Restoring functioning to achieve remission

Speaker:
Michael Landgrebe, Germany

Sharing our patients’ experiences with agomelatine
Speaker:
Hans-Jürgen Möller, Germany
 Panel Discussion
Wednesday, 11 October 2017

 

Behandlungsmöglichkeiten bei schwerer oder rezidivierender Depression (LivaNova Deutschland GmbH)
11:45 - 13:15 | Room M8
Speaker:
Thomas E. Schläpfer, Germany
 
Speaker:
Here W. Folkerts, Germany
Learn More